文献速递肿瘤 PET/CT

64CuCl2 PET/CT在肌层浸润性膀胱癌检测与分期中的作用:与增强CT及18F-FDG PET/CT的比较

Role of 64CuCl2 PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and 18F-FDG PET/CT.
PubMed 文献 · J Nucl Med · 2024-09-03

该前瞻性研究纳入42例病理确诊的肌层浸润性膀胱癌患者,在2周内完成增强CT、18F-FDG PET/CT和64CuCl2 PET/CT。基于患者分析,增强CT和64CuCl2 PET/CT检测原发肿瘤的灵敏度高于18F-FDG PET/CT(P<0.001);两种PET方法在淋巴结分类中的特异度和准确度均高于增强CT(P<0.05)。基于病灶分析,64CuCl2 PET/CT在总体、淋巴结、骨骼和软组织病灶检测中优于18F-FDG PET/CT和增强CT。

要点

  • 64CuCl2 PET/CT检测原发肿瘤的灵敏度高于18F-FDG PET/CT(P<0.001)。
  • 两种PET方法在淋巴结分类中的特异度和准确度均高于增强CT(P<0.05)。
  • 基于病灶分析,64CuCl2 PET/CT在总体、淋巴结、骨骼和软组织检测中优于18F-FDG PET/CT和增强CT。

核心结论

  • 64CuCl2 PET/CT似乎是肌层浸润性膀胱癌分期/再分期的一种灵敏方法,在这些场景中可能代表一种「一站式」诊断方法。

研究设计与样本

  • 前瞻性纳入2021年9月至2023年1月在本机构转诊的病理确诊肌层浸润性膀胱癌拟行分期/再分期的患者。
  • 所有患者在2周内接受增强CT、18F-FDG PET/CT和64CuCl2 PET/CT检查。
  • 对全部可能受累区域(总体、膀胱壁、淋巴结、骨骼、肝脏、肺和盆腔软组织)进行基于患者和基于病灶的分析。
  • 共纳入42例患者(9例女性)。

主要发现

  • 36例(86%)有疾病证据,共353个疾病部位。
  • 基于患者分析,增强CT和64CuCl2 PET/CT检测原发肿瘤的灵敏度高于18F-FDG PET/CT(P<0.001)。
  • 基于患者分析,64CuCl2 PET/CT发现软组织病灶的灵敏度略高于18F-FDG PET/CT(P<0.05)。
  • 基于患者分析,两种PET方法在淋巴结病变分类中的特异度和准确度均高于增强CT(P<0.05)。
  • 基于病灶分析,64CuCl2 PET/CT在检测总体疾病定位、淋巴结(P<0.01)、骨骼(P<0.001)和软组织(P<0.05)方面优于18F-FDG PET/CT和增强CT(总体P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular imaging of muscle-invasive bladder cancer (MBC) is restricted to its locoregional and distant metastases, since most radiopharmaceuticals have a urinary excretion that limits the visualization of the primary tumor. 64CuCl2 , a positron-emitting radiotracer with nearly exclusive biliary elimination, could be well suited to exploring urinary tract neoplasms. In this study, we evaluated the feasibility of 64CuCl2-based staging of patients with MBC; furthermore, we compared the diagnostic capability of this method with those of the current gold standards, that is, contrast-enhanced CT (ceCT) and 18F-FDG PET/CT. Methods: We prospectively enrolled patients referred to our institution for pathology-confirmed MBC staging/restaging between September 2021 and January 2023. All patients underwent ceCT, 18F-FDG, and 64CuCl2 PET/CT within 2 wk. Patient-based analysis and lesion-based analysis were performed for all of the potentially affected districts (overall, bladder wall, lymph nodes, skeleton, liver, lung, and pelvic soft tissue). Results: Forty-two patients (9 women) were enrolled. Thirty-six (86%) had evidence of disease, with a total of 353 disease sites. On patient-based analysis, ceCT and 64CuCl2 PET/CT showed higher sensitivity than 18F-FDG PET/CT in detecting the primary tumor (P < 0.001); moreover, 64CuCl2 PET/CT was slightly more sensitive than 18F-FDG PET/CT in disclosing soft-tissue lesions (P < 0.05). Both PET methods were more specific and accurate than ceCT in classifying nodal lesions (P < 0.05). On lesion-based analysis, 64CuCl2 PET/CT outperformed 18F-FDG PET/CT and ceCT in detecting disease localizations overall (P < 0.001), in the lymph nodes (P < 0.01), in the skeleton (P < 0.001), and in the soft tissue (P < 0.05). Conclusion: 64CuCl2 PET/CT appears to be a sensitive modality for staging/restaging of MBC and might represent a "one-stop shop" diagnostic method in these scenarios.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Piccardo A, Bottoni G, Puppo C, et al. Role of 64CuCl2 PET/CT in Detecting and Staging Muscle-Invasive Bladder Cancer: Comparison with Contrast-Enhanced CT and 18F-FDG PET/CT. J Nucl Med. 2024. PMID: 39054284. doi:10.2967/jnumed.124.267474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。